Early hyperprolactinaemia in acute psychiatric inpatients: a cross-sectional study

Iperprolattinemia precoce in pazienti ricoverati in spdc: uno studio trasversale

G. Pigato (1), G.V.M. Piazzon (1), A. Di Florio (2), M. Ermani (3), T. Toffanin (3), G.I. Perini (1,3)

1 Department of Neurosciences, Section of Psychiatry, University-Hospital of Padova, Padova, Italy; 2 Institute of Psychological Medicine and Clinical Neurosciences, Cardiff University School of Medicine, Cardiff, UK; 3 Department of Neurosciences, Section of Neurology, University-Hospital of Padova, Padova, Italy; 4 Department of Psychiatry, ULSS 7, Pieve di Soligo, Treviso, Italy



Hyperprolactinaemia is an important adverse effect of many drugs. Few naturalistic studies have compared rates of hyperprolactinaemia across psychotropic medications, especially antidepressants. In this cross-sectional study, we aimed to: 1) assess the prevalence and severity of hyperprolactinaemia in a sample of individuals with severe acute psychiatric illnesses, and 2) identify the demographic and clinical factors that might influence levels of prolactinaemia.


225 individuals were consecutively recruited. Individuals with any medical conditions and other not psychopharmacological drugs known to induce hyperprolactinemia were excluded. Blood samples were collected prior to breakfast and medication administration. Prolactin levels were measured by an electrochemiluminescent immunoassay.


About 2 in 3 individuals treated with antipsychotics had hyperprolactinaemia. Treatment with antipsychotics, particularly risperidone (p = 0.002), and young age (p<0.005) were associated with hyperprolactinaemia. We did not find any association between antidepressants and hyperprolactinaemia (p = 0.07).


Hyperprolactinaemia is a common and early phenomenon among individuals treated for acute psychiatric disorders, especially in younger patients and women.

Scarica il PDF